Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after: Implantation of embryonal carcinoma- derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor

Journal of Neurosurgery

Volumn 92, Issue 4, 2000, Pages 659-670

  Nakao, Naoyuki ^a   Yokote, Hideyuki ^a   Nakai, Kunio ^a   Itakura, Toru ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

6 Hydroxydopamine; Cell implantation; Gene therapy; Neural progenitor cell; Parkinson's disease; Rat

Indexed keywords

COMPLEMENTARY DNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; OXIDOPAMINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; EMBRYO; EMBRYONAL CARCINOMA; GENE THERAPY; GENETIC ENGINEERING; MOUSE; NERVE CELL DIFFERENTIATION; NERVE REGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

EID: 0034109787     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.2000.92.4.0659     Document Type: Article

References (48)

1. Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci 12:366-375, 1989
2. Beck KD, Valverde J, Alexi T, et al: Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373:339-341, 1995
3. Bilang-Bleuel A, Revah F, Colin P, et al: Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 94:8818-8823, 1997
4. Björklund A, Lindvall O: Dopamine in dendrites of substantia nigra neurons: suggestions for a role in dendritic terminals. Brain Res 83:531-537, 1975
5. Björklund A, Rosenblad C, Winkler C, et al: Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4:186-200, 1997
6. Bowenkamp KE, Hoffmann AF, Gerhardt GA, et al: Glial cell line-derived neurotrophic factor supports survival of injured midbrain dopaminergic neurons. J Comp Neurol 355: 479-489, 1995
7. Choi-Lundberg DL, Lin Q, Chang YN, et al: Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275:838-841, 1997
8. DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285, 1990
9. During MJ, Leone P: Targets for gene therapy of Parkinson's disease: growth factors, signal transduction, and promoters. Exp Neurol 144:74-81, 1997
10. Fisher L, Ray J: In vivo and ex vivo gene transfer to the brain. Curr Opin Neurobiol 4:735-741, 1994
11. Gage FH, Fisher L: Genetically modified cells for intracerebral transplantation, in Lindvall O (ed): Restoration of Brain Function by Tissue Transplantation. Berlin: Springer-Verlag, 1993, pp 51-60
12. Gash DM, Zhang Z, Gerhardt G: Neuroprotective and neurorestorative properties of GDNF. Ann Neurol 44 (Suppl 3): 121-125, 1998
13. Gash DM, Zhang Z, Ovadia A, et al: Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255, 1996
14. Geffen LB, Jessell TM, Cuello AC, et al: Release of dopamine from dendrites in rat substantia nigra. Nature 260:258-260, 1976
15. Hoffer BJ, Hoffmann A, Bowenkamp K, et al: Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182: 107-111, 1994
16. Hudson J, Granholm AC, Gerhardt GA, et al: Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo Brain Res Bull 36:425-432, 1995
17. Jackson EA, Kelly PH: Role of nigral dopamine in amphetamine-induced locomotor activity. Brain Res 278:366-369, 1983
18. Jellinger K: Overview of morphological changes in Parkinson's disease. Adv Neurol 45:1-18, 1987
19. 125I] glial cell line-derived neurotrophic factor to the rat CNS following osmotic blood-brain barrier modification. Neurosci Lett 220: 187-190, 1996
20. Jones-Villeneuve EMV, McBurney MW, Rogers KA, et al: Retinoic acid induces embryonal carcinoma cells 10 differentiate into neurons and glial cells. J Cell Biol 94:253-262, 1982
21. Kleppner SR, Robinson KA, Trojanowski JQ, et al: Transplanted human neurons derived from a teratocarcinoma cell line (NTera-2) mature, integrate, and survive for over 1 year in the nude mouse brain. J Comp Neurol 357:618-632, 1995
22. Lin LFH, Doherty DH, Lile JD, et al: GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132, 1993
23. Lindvall O: Neural transplantation in Parkinson's disease, in Dunnett SB, Björklund A (eds): Functional Neural Transplantation. New York: Raven Press, 1994, pp 103-107
24. Lundberg C, Martínez-Serrano A, Cattaneo E, et al: Survival, integration, and differentiation of neural stem cell lines after transplantation to the adult rat striatum. Exp Neurol 145: 342-360, 1997
25. Mandel RJ, Spratt SK, Snyder RO, et al: Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 94: 14083-14088, 1997
26. Marsden CD: Parkinson's disease. J Neurol Neurosurg Psychiatry 57:672-681, 1994
27. Martínez-Serrano A, Björklund A: Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J Neurosci 16:4604-4616, 1996
28. Martínez-Serrano A, Lundberg C, Horellou P, et al: CNS-derived neural progenitor cells for gene transfer of nerve growth factor to the adult rat brain: complete rescue of axotomized cholinergic neurons after transplantation into the septum. J Neurosci 15:5668-5680, 1995
29. McBurney MW, Rogers BJ: Isolation of male embryonal carcinoma cells and their chromosome replication pattern. Dev Biol 89:503-508, 1982
30. Morassutti DJ, Staines WA, Magnuson DSK, et al: Murine embryonal carcinoma-derived neurons survive and mature following transplantation into adult rat striatum. Neuroscience 58: 753-763, 1994
31. Mullen RJ, Buck CR, Smith AM: NeuN: a neuronal specific nuclear protein in vertebrates. Development 116:201-211, 1992
32. Nakao N, Frodl EM, Widner H, et al: Overexpressed Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nat Med 1:226-231, 1995
33. Nakao N, Nakai K, Itakura T: Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro. Brain Res 777:202-209, 1997
34. Olanow CW, Kordower JH, Freeman TB: Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 19:102-109, 1996
35. Olson L: Toward trophic treatment in parkinsonism: a primate step. Nat Med 2:400-401, 1996
36. Paxinos G, Watson C: The Rat Brain in Stereotaxic Coordinates. San Diego: Academic Press, 1984
37. Philips MF, Muir JK, Saatman KE, et al: Survival and integration of transplanted postmitotic human neurons following experimental brain injury in immunocompetent rats. J Neurosurg 90:116-124, 1999
38. Robertson GS, Damsma G, Fibiger HC: Characterization of dopamine release in the substantia nigra by in vivo microdialysis in freely moving rats. J Neurosci 11:2209-2216, 1991
39. Robertson GS, Robertson HA: Evidence that L-DOPA-induced rotational behavior is dependent on both striatal and nigral mechanisms. J Neurosci 9:3326-3331, 1989
40. Robertson GS, Robertson HA: Evidence that the substantia nigra is a site of action of L-DOPA. Neurosci Lett 89: 204-208, 1988
41. Rosenblad C, Martínez-Serrano A, Björklund A: Intrastriatal glial cell line-derived neurotrophic factor promotes sprouting of spared nigrostriatal dopaminergic afferents and induces recovery of function in a rat model of Parkinson's disease. Neuroscience 82:129-137, 1998
42. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989
43. Sauer H, Oertel WH: Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde and immunocytochemical study in the rat. Neuroscience 59:401-415, 1994
44. Sauer H, Rosenblad C, Björklund A: Glial cell line-derived neurotrophic factor but not transforming growth factor β3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion. Proc Natl Acad Sci USA 92:8935-8939, 1995
45. Snyder EY, Senut MC: The use of nonneuronal cells for gene delivery. Neurobiol Dis 4:69-102, 1997
46. Tomac A, Lindqvist E, Lin LFH, et al: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339, 1995
47. Tseng JL, Baetge EE, Zurn AD, et al: GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine. J Neurosci 17:325-333, 1997
48. Winkler C, Sauer H, Lee CS, et al: Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 16: 7206-7215, 1996